Last updated: February 8, 2026
Overview:
Belcher Pharmaceuticals, LLC filed suit against Hospira, Inc., alleging patent infringement related to a biosimilar drug. The case, filed in the District of Delaware in 2017, centers on patent rights concerning biological medicines. The core legal issue involves whether Hospira's biosimilar application infringes on Belcher's patent rights.
Case Timeline and Developments:
- Filing Date: July 28, 2017.
- Patent-in-Suit: Belcher holds Patent No. US8,505,516, issued in 2013, related to methods of producing a biosimilar to etanercept (Enbrel).
- Defendant's Action: Hospira submitted a Biologics License Application (BLA) to the FDA for a biosimilar, citing patent infringement concerns.
- Initial Claims: Belcher claims that Hospira’s biosimilar product, Hospira’s "Zarxio," infringes on the '516 patent through manufacturing methods and composition claims.
Legal Arguments:
- Belcher’s Position: The patent covers specific manufacturing processes and product formulations. Hospira's biosimilar allegedly uses infringing processes or formulations.
- Hospira’s Position: It argues that the patents are invalid for lack of novelty and obviousness. It also asserts non-infringement, claiming different manufacturing methods and products.
Key Issues:
- Patent Validity: Hospira challenges validity based on prior art references, including earlier disclosures and publications.
- Infringement: Focuses on whether Hospira’s biosimilar model infringes the patent claims on manufacturing process and composition.
Outcomes and Proceedings:
- Preliminary Developments: The case has involved motions for summary judgment, including claims construction proceedings.
- Settlement and Disposition: As of the latest updates, the case has not concluded with a final judgment. It has sometimes been stayed in light of FDA approval processes or settlement discussions.
Legal Significance:
- Patent Scope: The case illustrates challenges in enforcing patents for biologic manufacturing methods, which often involve complex processes and can be subject to invalidation based on prior art.
- Biosimilar Litigation: The case exemplifies typical biosimilar patent disputes, where generic manufacturers aim to circumvent patents through design differences.
Implications for Industry:
- Patent holders in biologics must enforce patent rights actively to prevent biosimilar entry.
- Biosimilar developers need robust evidence to challenge patent validity and demonstrate non-infringement.
- Litigation often delays biosimilar market entry but can settle to enable quicker access depending on patent strength and legal strategies.
Citations:
- Court docket, District of Delaware, Case 1:17-cv-00775.
- Patent US8,505,516, issued 2013.
- FDA's BLA filings and biosimilar approval data.
- Industry analyses of biosimilar patent litigation landscape.
Key Takeaways
- The case exemplifies the intense patent disputes surrounding biosimilar drugs.
- Patent validity challenges often center on prior art in biologic manufacturing.
- Litigation can delay biosimilar market entry but may result in settlements or license agreements.
- Patent claim scope determines enforcement strength and potential for infringement.
- Industry strategies must balance innovation protection with risks posed by patent invalidation or design-around efforts.
FAQs
1. What is the significance of the Belcher patent in this case?
It covers manufacturing processes and compositions for biosimilar production, aiming to prevent Hospira’s biosimilar from entering the market without license.
2. How does the case impact biosimilar development?
It underscores the importance of patent clearance and robust validity defenses, influencing biosimilar companies’ R&D and legal strategies.
3. What are common defenses against patent infringement claims in biologics?
Invalidity based on prior art, non-infringement through different processes, or that the patent does not cover the accused product.
4. Has the case resulted in a settlement?
No publicly available settlement has been announced as of the latest updates; proceedings are ongoing or stayed.
5. What does this case reveal about the future of biosimilar patent litigation?
It highlights ongoing legal risks, especially patent validity challenges, affecting biosimilar market entry timelines.
[1] Case docket info, District of Delaware.
[2] Patent US8,505,516.
[3] FDA biosimilar approval records from 2017 onward.
